
- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產品
- 聯(lián)系我們
別名: BMS-936558, ONO-4538, MDX-1106 中文名稱:納武單抗
Nivolumab (anti-PD-1)是一種通過基因工程改造的、人類免疫球蛋白(Ig)G4單克隆抗體,靶向具有負向免疫調節(jié)功能的人類細胞表面受體程序性死亡-1(PD-1, PCD-1);也是一種抑制劑,具有免疫檢查點抑制活性和抗腫瘤活性;MW:143.597 KD。
客戶使用Selleck的Nivolumab (anti-PD-1)發(fā)表文獻87篇
| 抑制劑名稱 | 引文數(shù)量 | PD-1/PD-L1 interaction | PD-1 | PD-L1 | PD-1/PD-L1 | 其他靶點 |
|---|---|---|---|---|---|---|
| GS-4224 | 0 | |||||
| INCB086550 | 1 | |||||
| BMS-1001 | 0 | |||||
| BMS-1166 | 11 | |||||
| Durvalumab (anti-PD-L1) | 19 | PD-L1/CD80 | ||||
| Atezolizumab (anti-PD-L1) | 72 | |||||
| Nivolumab (anti-PD-1) | 86 | PD-1/PD-L2 interaction | ||||
| PD-1/PD-L1 Inhibitor 3 | 13 | |||||
| BMS-1 | 13 | |||||
| BMS-202 | 26 | |||||
| CA-170 (AUPM-170) | 0 | |||||
| SR 0987 | 1 | IL17,RORγt | ||||
| Spartalizumab (anti-PD-1) | 4 | |||||
| Camrelizumab (anti-PD-1) | 2 | |||||
| AUNP-12 | 3 | |||||
| Pembrolizumab (anti-PD-1) | 75 |
| 產品描述 | Nivolumab (anti-PD-1)是一種通過基因工程改造的、人類免疫球蛋白(Ig)G4單克隆抗體,靶向具有負向免疫調節(jié)功能的人類細胞表面受體程序性死亡-1(PD-1, PCD-1);也是一種抑制劑,具有免疫檢查點抑制活性和抗腫瘤活性;MW:143.597 KD。 | ||||
|---|---|---|---|---|---|
| 靶點 |
|
|
| CAS號 | 946414-94-4 |
|---|---|
| 配制 | 100 mM Pro-Ac, 20 mM Arg, pH5.0 |
| 推薦同型對照 | Human IgG4 |
| 來源 | CHO cells |
| 除菌 | 0.2 μM filtered |
| 儲存條件(自收到貨起) | Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Selleck收集了市面上此靶點抗體的常見克隆號,并調查了這些克隆在文獻中的使用情況(數(shù)據(jù)截至2024年9月)。結果顯示,Selleck選擇的克隆號更廣泛被使用。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
How to store the antibody?
回答:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.